Acetyl-L-Carnitine

Common (>10% at high doses, lower at 500 mg)

• GI upset (nausea, cramping, diarrhea) — primarily at >3 g/day; uncommon at 500 mg.
• Mild restlessness / overstimulation — dose-dependent; uncommon at 500 mg AM.

Less common (1-10%)

• Insomnia — especially with evening dosing.
• Headache.
• Vivid / unpleasant dreams.
• "Fishy" body odor — gut-microbiome-mediated TMA production exceeds FMO3 capacity to oxidize it. Worse in FMO3 hypomorphs (see Pharmacogenomics).

Rare-serious (<1% but worth knowing)

• Mania / psychosis precipitation in bipolar disorder — multiple case reports document hypomanic/manic episodes triggered by ALCAR in BPI patients, including in remission. Contraindicated in bipolar disorder without psychiatric supervision.
• Seizure exacerbation — case reports in epilepsy patients of increased seizure frequency on L-carnitine; ALCAR likely shares risk. Avoid if seizure history.
• Hyperthyroid symptom modulation — L-carnitine antagonizes T3/T4 entry into cell nuclei; 2-4 g/day can attenuate hyperthyroid symptoms (this can be desirable in hyperthyroidism but problematic in hypothyroid patients on replacement).

TMAO / cardiovascular risk — FLAGGED PROMINENTLY

This is the single most important safety concern with ALCAR and the reason this verdict is OPTIONAL-ADD rather than STRONG-CANDIDATE for a healthy 20-year-old.

The data:

• A 2025 study (Krims-Davis et al, Molecular Nutrition & Food Research) directly compared L-carnitine vs acetylcarnitine: a single 1.5 g dose increased plasma TMAO >30-fold above baseline (from 2-3 µM to 40-50 µM). This applies to both forms — ALCAR is not a TMAO-safer alternative.
• Acetylcarnitine has ~7.7× lower bioavailability than L-carnitine (much is hydrolyzed in gut to L-carnitine + acetate before absorption), which means gut bacteria see the L-carnitine and convert it to TMA, which the liver oxidizes to TMAO via FMO3.
• TMAO is mechanistically linked to atherosclerosis (foam-cell formation, platelet hyperreactivity, endothelial dysfunction). The 2025 MESA study (>6,000 participants) found TMAO associated with incident cardiovascular events.
• Mendelian randomization data on whether L-carnitine itself is causally cardioprotective vs harmful is mixed (2022 PMC study, "friend or foe?").

What this means for Dylan (20yo, no atherosclerosis, MMA cardiovascular base):

• Acute TMAO elevation in a young, lean, fit person with no plaque is a much smaller absolute risk than chronic TMAO elevation in a 60-year-old with metabolic syndrome.
• But the risk isn't zero and it's the type of slow, mechanism-driven process where 30+ years of daily 30× TMAO elevation is exactly the wrong intervention for someone whose explicit priority #3 is longevity.

Mitigation strategies (do these if continuing ALCAR long-term):

1. Cycle: 8-12 weeks on, 4 weeks off. Allows TMAO to clear (TMAO half-life ~5-9 hours, but chronic baseline takes weeks to normalize).
2. Pre-load gut with TMAO-suppressing diet: high fiber (resistant starch, oats, legumes), polyphenols (berries, EVOO, dark chocolate), allicin/raw garlic (gut TMA-lyase inhibitor — acutely lowers TMAO), and a Mediterranean-pattern overall.
3. Probiotics: specific strains (Lactobacillus plantarum) modulate gut TMA production; evidence is preliminary but mechanistically clean.
4. Track TMAO directly: Cleveland HeartLab and others offer plasma TMAO assays. Strongly recommended if Dylan plans to use ALCAR daily for >6 months. Add to the June bloodwork panel.
5. Limit dose: 500 mg gives maybe half the TMAO bump of 1.5 g; the cognitive benefit at 500 mg is comparable for healthy users. Don't escalate without reason.

Specific watch periods

• First 2 weeks: GI tolerance, sleep impact, mood changes.
• 3 months: confirm subjective benefit; if null, drop the supplement.
• 6 months: check TMAO, lipid panel, hs-CRP. Reassess.